Drug Profile
Research programme: tumour necrosis factor alpha-binding polymers - Semorex Technologies/Pharmacoidea
Latest Information Update: 28 Apr 2019
Price :
$50
*
At a glance
- Originator Semorex
- Developer Pharmacoidea; Semorex
- Class Polymers
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Crohn's disease
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for research development in Crohn's-disease in Hungary (PO)
- 28 Apr 2019 No recent reports of development identified for research development in Crohn's-disease in Israel (PO)